Scientific article

Valves cardiaques biologiques et anticoagulation

Published inRevue médicale suisse, vol. 4, no. 175, p. 2198-2202
Publication date2008

Cardiac valve replacement is associated with a thromboembolic risk, particularly during the immediate postoperative period. The current anticoagulation recommendations for biological valves are variable and their application by the surgical centers is unconstant. Some centers continue to anticoagulate all patients who receive a heart valve replacement for 3 months, without distinction of valve position (mitral or aortic) at the cost of bleeding complications. However, more recent studies suggest that anticoagulation may not be necessary for biological valves in aortic position in the absence of associated embolic risk factors. Prospective and randomized studies are still needed to establish more definitive evidence regarding the prevention of thromboembolism for bioprostheses.

  • Anticoagulants
  • Bioprosthesis
  • Heart Valve Prosthesis
  • Humans
  • Thromboembolism
Citation (ISO format)
CHATTON CHAMBAZ, Isabelle, NENDAZ, Mathieu. Valves cardiaques biologiques et anticoagulation. In: Revue médicale suisse, 2008, vol. 4, n° 175, p. 2198–2202.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation07/12/2010 2:37:43 PM
First validation07/12/2010 2:37:43 PM
Update time03/14/2023 3:55:02 PM
Status update03/14/2023 3:55:02 PM
Last indexation01/15/2024 8:55:38 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack